GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » Shiller PE Ratio

Fennec Pharmaceuticals (STU:RV41) Shiller PE Ratio : (As of May. 27, 2024)


View and export this data going back to . Start your Free Trial

What is Fennec Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Fennec Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Fennec Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Shiller PE Ratio Chart

Fennec Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fennec Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fennec Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Fennec Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Shiller PE Ratio falls into.



Fennec Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Fennec Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Fennec Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.377/131.7762*131.7762
=0.377

Current CPI (Mar. 2024) = 131.7762.

Fennec Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.059 100.560 -0.077
201409 0.023 100.428 0.030
201412 0.114 99.070 0.152
201503 0.009 99.621 0.012
201506 -0.018 100.684 -0.024
201509 -0.009 100.392 -0.012
201512 -0.046 99.792 -0.061
201603 -0.036 100.470 -0.047
201606 -0.053 101.688 -0.069
201609 -0.036 101.861 -0.047
201612 -0.085 101.863 -0.110
201703 -0.056 102.862 -0.072
201706 -0.098 103.349 -0.125
201709 -0.126 104.136 -0.159
201712 -0.127 104.011 -0.161
201803 -0.073 105.290 -0.091
201806 -0.120 106.317 -0.149
201809 -0.120 106.507 -0.148
201812 -0.132 105.998 -0.164
201903 -0.115 107.251 -0.141
201906 -0.212 108.070 -0.259
201909 -0.082 108.329 -0.100
201912 -0.162 108.420 -0.197
202003 -0.172 108.902 -0.208
202006 -0.186 108.767 -0.225
202009 -0.204 109.815 -0.245
202012 -0.099 109.897 -0.119
202103 -0.151 111.754 -0.178
202106 -0.125 114.631 -0.144
202109 -0.136 115.734 -0.155
202112 -0.150 117.630 -0.168
202203 -0.127 121.301 -0.138
202206 -0.180 125.017 -0.190
202209 -0.313 125.227 -0.329
202212 -0.236 125.222 -0.248
202303 -0.215 127.348 -0.222
202306 -0.194 128.729 -0.199
202309 -0.066 129.860 -0.067
202312 -0.092 129.419 -0.094
202403 0.377 131.776 0.377

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Fennec Pharmaceuticals  (STU:RV41) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Fennec Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals (STU:RV41) Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals (STU:RV41) Headlines

No Headlines